QHSLab, Inc. (OTCMKTS:USAQ) recently announced its latest development in the form of a Consulting Agreement signed with Dr. Juan D. Oms, MD, FAPA, on October 18. The consulting agreement aims to leverage Dr. Oms’ expertise in psychiatry and behavioral health to enhance the company’s strategic advisory services. One of the key terms of the agreement includes a one-time stock payment of 100,000 shares of QHSLab’s common stock to Dr. Oms.
Dr. Oms boasts an impressive background as a Board-Certified Psychiatrist and Fellow of the American Psychiatric Association. His extensive experience includes leadership roles such as Medical Director of various treatment programs and his current position as Chairman of the Psychiatry Residency Program at Southern Winds Hospital. Known for his work in developing integrated mental health services, Dr. Oms is well-positioned to assist QHSLab in expanding its digital health solutions, particularly in the areas of mental health and primary care providers.
Additionally, QHSLab disclosed the issuance of a press release on October 22, titled “QHSLab, Inc. Announces Juan D. Oms MD, FAPA as Psychiatry and Behavioral Health Adviser.” The press release outlined the strategic addition of Dr. Oms to QHSLab’s team and highlighted the shared vision of integrating advanced digital healthcare solutions to support patients’ mental health and substance-related needs in primary care settings.
Moving forward, as QHSLab continues to focus on digital health initiatives, Dr. Oms’ expertise is anticipated to play a pivotal role in advancing the company’s capabilities in behavioral health and chronic care management. This partnership is poised to enhance patient outcomes and overall healthcare services in primary care settings and beyond.
Investors and stakeholders interested in learning more about QHSLab and its recent developments can access additional information on the company’s official website and various social media channels.
This release may contain forward-looking statements that are subject to risks and uncertainties, including market trends, product releases, and regulatory factors affecting actual results. The company encourages investors to review its filings with the Securities and Exchange Commission for a comprehensive understanding of these factors.
For further information, please visit QHSLab Inc.’s official website.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read QHSLab’s 8K filing here.
About QHSLab
QHSLab, Inc, a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine.
See Also
- Five stocks we like better than QHSLab
- ESG Stocks, What Investors Should Know
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Insider Trading – What You Need to Know
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Overbought Stocks Explained: Should You Trade Them?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
